An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant
This work was supported by grants from the Japan Program for Infectious Diseases Research and Infrastructure (JP25wm0125002), the Japan Initiative for World-leading Vaccine Research and Development Centers (JP253fa627001), and the Vaccine Development project (JP21nf0101625) from the Japan Agency for Medical Research and Development, and the National Institutes of Allergy and Infectious DiseasesCenter for Research on Influenza Pathogenesis and Transmission (CRIPT) (75N93021C00014).
Authors
- Shilpi Jain (ORCID: https://orcid.org/0000-0002-5638-0298)
- Ryuta Uraki (ORCID: https://orcid.org/0000-0003-0890-1922)
- Kazuki Miyaji
- Nao Jounai
- Mehul S. Suthar (ORCID: https://orcid.org/0000-0002-2686-8380)
- Tiago J. S. Lopes (ORCID: https://orcid.org/0000-0001-9605-5177)
- Seiya Yamayoshi (ORCID: https://orcid.org/0000-0001-7768-5157)
- Maki Kiso (ORCID: https://orcid.org/0009-0004-3645-0967)
- Peter Halfmann (ORCID: https://orcid.org/0000-0002-1648-1625)
- Yoshihiro Kawaoka (ORCID: https://orcid.org/0000-0001-5061-8296)
- Mutsumi Ito
- Fumihiko Takeshita (ORCID: https://orcid.org/0009-0001-7124-8877)
Institutions
- Emory Healthcare (US)
- University of Wisconsin–Madison (US)
- Emory University (US)
- Tokyo University of Science (JP)
- National Institute of Infectious Diseases (JP)
- Daiichi-Sankyo (Japan) (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- EBioMedicine
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.ebiom.2025.105794
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Daiichi-Sankyo
- Shionogi
- Otsuka Pharmaceutical
- FUJIFILM Toyama Chemical
- Daiichi Sankyo Europe